Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Tanezumab is a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for chronic pain. This phase IIB study investigated the efficacy and safety of tanezumab for chronic low back pain vs placebo and naproxen. Patients (N=1347) received intravenous tanezumab (5, 10, or 20mg every 8weeks), naproxen (500mg twice daily), or placebo. The primary efficacy end point was mean change in daily average low back pain intensity (LBPI) from baseline to week 16. Secondary end points included mean change from baseline to week 16 in the Roland Morris Disability Questionnaire and Patient's Global Assessment (PGA) of low back pain. Tanezumab 10 and 20mg had similar efficacy profiles and significantly improved LBPI, Roland Morris Disability Questionnaire, and PGA scores vs both placebo and naproxen (P⩽.05). Tanezumab 5mg provided improvement of PGA scores vs placebo (P⩽.05), and naproxen resulted in significant improvement of LBPI vs placebo (P⩽.05). Adverse event incidence was comparable across tanezumab doses but higher than with placebo or naproxen. Arthralgia, pain in extremity, headache, and paresthesia were the most commonly reported adverse events by tanezumab-treated patients. The most frequently reported adverse events resulting in discontinuation of tanezumab treatment were arthralgia and paresthesia; the highest frequency was observed with tanezumab 20mg (both 1.4%). Serious adverse event incidence was similar across treatments. In conclusion, tanezumab provided significantly greater improvement in pain, function, and global scores vs placebo and naproxen in patients with chronic low back pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
Dworkin, R. H., Turk, D. C., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Katz, N. P., Kerns, R. D., Stucki, G., Allen, R. R., Bellamy, N., et al. (2005) · Pain · doi:10.1016/j.pain.2004.09.012 · Cited by 3,732
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
Turk, D. C., Dworkin, R. H., Allen, R. R., Bellamy, N., Brandenburg, N., Carr, D. B., Cleeland, C., Dionne, R., Farrar, J. T., Galer, B. S., et al. (2003) · Pain · doi:10.1016/j.pain.2003.08.001 · Cited by 3,510
Chou, R., Qaseem, A., Snow, V., Casey, D., Cross, J. T., Shekelle, P., Owens, D. K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians and the American College of Physicians/American Pain Society Low Back Pain Guidelines Panel* (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-7-200710020-00006 · Cited by 2,718 · cited 14×
“Naproxen was associated with only a modest benefit in this study, and these results corroborate previous studies of NSAIDs or selective COX-2 inhibitors in the treatment of chronic low back pain [10,37].”
BackgroundResultInfluentialChapter 4 European guidelines for the management of chronic nonspecific low back pain
Airaksinen, O., Brox, J. I., Cedraschi, C., Hildebrandt, J., Klaber-Moffett, J., Kovacs, F., Mannion, A. F., Reis, S., Staal, J. B., Ursin, H., et al. (2006) · European Spine Journal · doi:10.1007/s00586-006-1072-1 · Cited by 2,594 · cited 1×
“Pharmacological treatment often includes use of opioids and/or nonsteroidal anti-inflammatory drugs (NSAIDs) despite only modest efficacy [2,4,8].”
Deyo, R. A., & Weinstein, J. N. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440508 · Cited by 1,675
Outcome Measures for Low Back Pain Research: A Proposal for Standardized Use
Deyo, R. A., Battie, M., Beurskens, A. J. H. M., Bombardier, C., Croft, P., Koes, B., Malmivaara, A., Roland, M., Von Korff, M., & Waddell, G. (1998) · Spine · doi:10.1097/00007632-199809150-00018 · Cited by 1,229
Chou, R., & Huffman, L. H. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-7-200710020-00007 · Cited by 1,045 · cited 1×
“Generally, treatment of chronic low back pain involves a multimodal approach utilizing both pharmacological (single or multiple agents) and nonpharmacological measures [8,9].”
Background
Cited by
Qaseem, A., Wilt, T. J., McLean, R. M., Forciea, M. A., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m16-2367 · Cited by 3,234
“NSAIDs Moderate-quality evidence showed that NSAIDs were associated with small to moderate pain improvement compared with placebo (14, 28, 29).”
BackgroundChou, R., Deyo, R., Friedly, J., Skelly, A., Weimer, M., Fu, R., Dana, T., Kraegel, P., Griffin, J., & Grusing, S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2458 · Cited by 864
Lyu, F.-J., Cui, H., Pan, H., MC Cheung, K., Cao, X., Iatridis, J. C., & Zheng, Z. (2021) · Bone Research · doi:10.1038/s41413-020-00125-x · Cited by 474
Non-steroidal anti-inflammatory drugs for chronic low back pain
Enthoven, W. T., Roelofs, P. D., Deyo, R. A., van Tulder, M. W., & Koes, B. W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012087 · Cited by 399
Nerve Growth Factor and Pain Mechanisms
Denk, F., Bennett, D. L., & McMahon, S. B. (2017) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-072116-031121 · Cited by 257
Metadata
- Authors
- Kivitz, A. J., Gimbel, J. S., Bramson, C., Nemeth, M. A., Keller, D. S., Brown, M. T., West, C. R., & Verburg, K. M.
- Venue
- Pain
- Published
- 2013-07
- Volume
- 154
- Issue
- 7
- Pages
- 1009-1021
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2049593278
- Cited by
- 145
- References
- 7
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. https://app.cochat.ai/papers/10.1016/j.pain.2013.03.006
- The paper
- Kivitz, A. J., Gimbel, J. S., Bramson, C., Nemeth, M. A., Keller, D. S., Brown, M. T., West, C. R., & Verburg, K. M. (2013). Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain. https://doi.org/10.1016/j.pain.2013.03.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.